Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
          • Financials
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • What is a Clinical Trial?
          • Your Involvement Matters
          • Current Trials & Studies
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • World FSHD Day
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Current Trials and Studies
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • Search
  • Financials
  • Patient Library
  • Blog
  • Calendar
  • JOIN US
  • Donate
  • JOIN US
  • Donate

Placing a BET on blocking DUX4

Home / FSHD Research / Placing a BET on blocking DUX4

Posted on: Nov 18, 2017

by FRAN SVERDRUP, PHD
St. Louis, Missouri

DUX4 is considered to be a key cause of muscle degeneration in FSH muscular dystrophy. This is why we are interested in finding drugs that “turn off” the production of DUX4, which would prevent the many detrimental activities of this toxic protein. Such drugs would potentially provide the first treatment option for slowing or stopping disease progression in FSHD.

By screening drug libraries in FSHD cells grown in the laboratory, we have identified two classes of drugs that turn off DUX4. One class are drugs that inhibit bromodomain and extra-terminal (BET) proteins, and the second are drugs that turn on beta adrenergic signaling (beta agonists). BET inhibitors are in clinical trials for cancer and other diseases, while beta agonists are widely used for asthma and chronic obstructive pulmonary disease.

These discoveries are important for two reasons. First, we can now explore the potential utility of these drug classes in directly treating FSHD. This is a very exciting prospect, but one that must be viewed with caution because significantly more work must be done before we can determine if these potential drugs would be safe and effective.

An equally exciting prospect is that studying how these drugs turn off DUX4 is likely to uncover additional drug targets. While the research we have published is preliminary, it raises hope that we will be able to treat FSHD with drugs that prevent or even reverse disease progression.

Editor’s note: This research received seed funding from the FSH Society, and was subsequently supported by NIH/NIAMS grant R01AR045203 (SJT); NIH/NINDS grant P01NS069539 (RT, SMvdM, SJT, FMS); NIH training grants T32CA009657 (AEC), T32GM007270 (SCS), and T32HG00035 (SCS); Friends of FSH Research (SJT); FSHD Canada Foundation (YH); Prinses Beatrix Spierfonds grant W.OP14-01 (SMvdM); and Spieren voor Spieren (SMvdM).

Reference
Campbell AE, Oliva J, Yates MP, Zhong JW, Shadle SC, Snider L, Singh N, Tai S, Hiramuki Y, Tawil R, van der Maarel SM, Tapscott SJ, Sverdrup FM. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. Skeletal Muscle. 2017;7:16. doi: 10.1186/s13395-017-0134-x.

Share

Filed Under: FSHD Research

Comments

  1. Debra Love says

    January 27, 2018 at 5:44 pm

    So thankful for all the doctors that are doing the research to find a cure for FSHD. These studies give me a ray of hope still. Please keep up the great work you are doing for us with this disease. May God bless you all abundantly!!

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

FSHD Society
P.O. Box 411617
Boston, MA 02241-1617

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by